Emergent Biosolutions (EBS) Competitors $8.24 +0.30 (+3.78%) Closing price 03:59 PM EasternExtended Trading$8.16 -0.08 (-0.91%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EBS vs. JNJ, MNKD, CLDX, BCRX, NVAX, INVA, DVAX, OPK, ZBIO, and GERNShould you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Johnson & Johnson (JNJ), MannKind (MNKD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), Dynavax Technologies (DVAX), OPKO Health (OPK), Zenas BioPharma (ZBIO), and Geron (GERN). These companies are all part of the "medical" sector. Emergent Biosolutions vs. Its Competitors Johnson & Johnson MannKind Celldex Therapeutics BioCryst Pharmaceuticals Novavax Innoviva Dynavax Technologies OPKO Health Zenas BioPharma Geron Johnson & Johnson (NYSE:JNJ) and Emergent Biosolutions (NYSE:EBS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Do institutionals & insiders have more ownership in JNJ or EBS? 69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 1.2% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor JNJ or EBS? In the previous week, Johnson & Johnson had 102 more articles in the media than Emergent Biosolutions. MarketBeat recorded 109 mentions for Johnson & Johnson and 7 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.41 beat Emergent Biosolutions' score of 0.85 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 89 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Emergent Biosolutions 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, JNJ or EBS? Johnson & Johnson has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Which has stronger earnings & valuation, JNJ or EBS? Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJohnson & Johnson$88.82B4.77$14.07B$9.3518.82Emergent Biosolutions$1.04B0.42-$190.60M$2.453.36 Do analysts rate JNJ or EBS? Johnson & Johnson presently has a consensus target price of $177.87, suggesting a potential upside of 1.08%. Emergent Biosolutions has a consensus target price of $13.50, suggesting a potential upside of 63.83%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, analysts plainly believe Emergent Biosolutions is more favorable than Johnson & Johnson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Johnson & Johnson 0 Sell rating(s) 10 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.62Emergent Biosolutions 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is JNJ or EBS more profitable? Johnson & Johnson has a net margin of 25.00% compared to Emergent Biosolutions' net margin of 16.38%. Johnson & Johnson's return on equity of 32.49% beat Emergent Biosolutions' return on equity.Company Net Margins Return on Equity Return on Assets Johnson & Johnson25.00% 32.49% 13.00% Emergent Biosolutions 16.38%24.63%8.97% SummaryJohnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks. Get Emergent Biosolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EBS vs. The Competition Export to ExcelMetricEmergent BiosolutionsMED IndustryMedical SectorNYSE ExchangeMarket Cap$439.60M$3.13B$5.76B$21.53BDividend YieldN/A2.37%5.74%3.50%P/E Ratio3.3620.6576.5529.96Price / Sales0.42386.12495.39100.70Price / Cash4.0545.3237.1724.62Price / Book0.929.6613.724.59Net Income-$190.60M-$53.02M$3.29B$999.97M7 Day Performance1.10%1.09%1.03%0.91%1 Month Performance-10.09%7.93%6.32%5.36%1 Year Performance17.71%10.48%81.16%14.36% Emergent Biosolutions Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EBSEmergent Biosolutions4.6525 of 5 stars$8.24+3.8%$13.50+63.8%+14.8%$439.60M$1.04B3.362,420JNJJohnson & Johnson4.7179 of 5 stars$177.49-0.3%$176.29-0.7%+4.9%$427.46B$90.63B18.98138,100Trending NewsAnalyst ForecastMNKDMannKind4.2941 of 5 stars$5.38-3.4%$11.17+107.6%-15.8%$1.65B$301.74M48.91400Analyst ForecastInsider TradeShort Interest ↓High Trading VolumeCLDXCelldex Therapeutics2.2144 of 5 stars$24.50+0.2%$46.67+90.5%-38.1%$1.63B$7.02M-8.14150Analyst ForecastBCRXBioCryst Pharmaceuticals4.2881 of 5 stars$7.70-2.7%$16.70+116.9%+0.0%$1.62B$557.51M-42.78530Positive NewsNVAXNovavax4.2182 of 5 stars$8.08+1.3%$14.29+76.8%-32.1%$1.31B$1.08B3.541,990INVAInnoviva4.843 of 5 stars$19.55+0.9%$42.75+118.7%+1.8%$1.23B$358.71M63.07100Positive NewsShort Interest ↓DVAXDynavax Technologies4.3206 of 5 stars$9.36-0.5%$24.33+160.0%-13.0%$1.10B$316.27M-20.35350OPKOPKO Health4.3564 of 5 stars$1.38-1.4%$2.75+99.3%-6.8%$1.10B$664.03M-5.522,997ZBIOZenas BioPharma1.1288 of 5 stars$21.95+8.5%$36.67+67.0%N/A$851.89M$15M-6.18N/AGERNGeron2.9128 of 5 stars$1.27flat$3.79+198.1%-70.8%$810.28M$164.45M-9.7770Positive News Related Companies and Tools Related Companies JNJ Alternatives MNKD Alternatives CLDX Alternatives BCRX Alternatives NVAX Alternatives INVA Alternatives DVAX Alternatives OPK Alternatives ZBIO Alternatives GERN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:EBS) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent Biosolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent Biosolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EBS Stock Alerts